MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Completed · Phase 3
Conditions studied: Open Angle Glaucoma, Ocular Hypertension
In brief
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Key facts
- Study ID
- NCT04630808
- Run by
- Nicox Ophthalmics, Inc.
- People needed
- 696
- Starts
- 2020-11-09
- Expected to finish
- 2025-06-25
- Last updated by the study team
- 2025-09-08
Who can join
Age: 18 and older, up to 84. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of open-angle glaucoma or ocular hypertension in both eyes
- Qualifying IOP at 3 time points through the day at 2 visits following washout of IOP-lowering medication, if applicable
- Qualifying best-corrected visual acuity in each eye
- Ability to provide informed consent and follow study instructions
You may not qualify if…
- Narrow anterior chamber angles or disqualifying corneal thickness in either eye
- Clinically significant ocular disease in either eye
- Previous complicated surgery or certain types of glaucoma surgery in either eye
- Incisional ocular surgery or severe trauma in either eye within the past 6 months
- Uncontrolled systemic disease
Where it is running
- Nicox Clinical Site — Chandler, Arizona, United States
- Nicox Clinical Site — Phoenix, Arizona, United States
- Nicox Clinical Site — Burbank, California, United States
- Nicox Clinical Site — Garden Grove, California, United States
- Nicox Clinical Site — Huntington Beach, California, United States
- Nicox Clinical Site — La Jolla, California, United States
- Nicox Clinical Site — Murrieta, California, United States
- Nicox Clinical Site — Newport Beach, California, United States
- Nicox Clinical Site — Pasadena, California, United States
- Nicox Clinical Site — Petaluma, California, United States
- Nicox Clinical Site — Redlands, California, United States
- Nicox Clinical Site — San Francisco, California, United States
- Nicox Clinical Site — Danbury, Connecticut, United States
- Nicox Clinical Site — Boynton Beach, Florida, United States
- Nicox Clinical Site — Delray Beach, Florida, United States
- Nicox Clinical Site — Fort Lauderdale, Florida, United States
- Nicox Clinical Site — Fort Myers, Florida, United States
- Nicox Clinical Site — Jacksonville, Florida, United States
- Nicox Clinical Site — Jupiter, Florida, United States
- Nicox Clinical Site — Lakeland, Florida, United States
- Nicox Clinical Site — Largo, Florida, United States
- Nicox Clinical Site — Mt. Dora, Florida, United States
- Nicox Clinical Site — Venice, Florida, United States
- Nicox Clinical Site — Morrow, Georgia, United States
- Nicox Clinical Site — Dothan, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.